Division of Neurology, Department of Internal Medicine IV, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan.
Division of Neurology, Department of Internal Medicine IV, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan.
J Neuroimmunol. 2018 Apr 15;317:84-89. doi: 10.1016/j.jneuroim.2018.01.007. Epub 2018 Jan 9.
To determine clinical features of neurologic disorders associated with anti-glutamic acid decarboxylase antibodies (anti-GAD-Ab), we examined titers and time-dependent changes of anti-GAD-Ab. Six patients, stiff person syndrome (2), cerebellar ataxia (1), limbic encephalitis (1), epilepsy (1), brainstem encephalitis (1), were compared with 87 type I diabetes mellitus (T1DM) patients without neurologic disorders. Anti-GAD-Ab titers and index were higher in neurologic disorders than in T1DM, suggesting intrathecal antibody synthesis. Anti-GAD-Ab titers in T1DM decreased over time, whereas they remained high in neurologic disorders. Immunotherapy improved neurological disorders and anti-GAD-Ab titers and index provide clinically meaningful information about their diagnostic accuracy.
为了确定与抗谷氨酸脱羧酶抗体（anti-GAD-Ab）相关的神经紊乱的临床特征，我们检测了抗-GAD-Ab 的滴度和时间依赖性变化。我们将 6 名患者（僵人综合征 2 例，小脑性共济失调 1 例，边缘性脑炎 1 例，癫痫 1 例，脑干脑炎 1 例）与 87 例无神经紊乱的 1 型糖尿病（T1DM）患者进行了比较。神经紊乱患者的抗-GAD-Ab 滴度和指数均高于 T1DM，提示鞘内抗体合成。T1DM 患者的抗-GAD-Ab 滴度随时间降低，而神经紊乱患者的抗-GAD-Ab 滴度仍然很高。免疫疗法改善了神经紊乱，抗-GAD-Ab 滴度和指数提供了关于其诊断准确性的有临床意义的信息。
